1. Medtech Insight
  2. >>Archive

Medtronic completes TransVascular acquisition:

Medtronic (Minneapolis, Minnesota) has completed its acquisition of Palo Alto, California firm TransVascular, which is developing catheter technology that may enable localised drug delivery in the vascular system. Medtronic plans to move Transvascular's operations to its own facility in Santa Rosa, California, where they will be integrated into Medtronic Vascular's coronary and peripheral divisions (see Clinica No 1070, p 10).

Medtronic (Minneapolis, Minnesota) has completed its acquisition of Palo Alto, California firm TransVascular, which is developing catheter technology that may enable localised drug delivery in the vascular system. Medtronic plans to move Transvascular's operations to its own facility in Santa Rosa, California, where they will be integrated into Medtronic Vascular's coronary and peripheral divisions (see Clinica No 1070, p 10).

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

UK MHRA Takes Stock, Seeks CMSO And Reveals Device Innovation Early Access Thinking

 
• By Ashley Yeo

Evolution of the MHRA and its offering to medtechs continues, with the hunt for a visionary chief medical and scientific officer and release of outline plans on early access to innovative devices, building on IDAP learnings.

US FDA Webinar Highlights 506J Expectations Amid Ongoing Supply Chain Vulnerabilities

 
• By Elizabeth Orr

A recent CDRH Learn module urges medical device manufacturers to report potential shortages early, even outside emergencies, to help prevent disruptions. Recent natural disasters underscore the need for resilient supply chains, and reported shortages may be added to an FDA list.

J&J MedTech’s Digital Head Pushes for Smarter, Standardized ORs With AI and Open Tech

 
• By Marion Webb

J&J’s global head of MedTech Digital envisions AI-powered connected operating suites within a decade. In an interview with Medtech Insight, Shan Jegatheeswaran discusses how J&J, together with partners like NVIDIA and AWS, is laying the foundation for open platforms for standardized surgeries.